Impact of pre-graft serology on risk of BKPyV infection post-renal transplantation

• Published in: Nephrology, dialysis, transplantation Vol. 37; no. 4; pp. 781 - 788
• Main Authors: Dakroub, Fatima, Touzé, Antoine, Sater, Fadi Abdel, Fiore, Toni, Morel, Virginie, Tinez, Claire, Helle, François, François, Catherine, Choukroun, Gabriel, Presne, Claire, Guillaume, Nicolas, Duverlie, Gilles, Castelain, Sandrine, Akl, Haidar, Brochot, Etienne
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 25-03-2022
• Subjects: BK Virus; Female; Human health and pathology; Humans; Kidney Transplantation - adverse effects; Life Sciences; Male; Polyomavirus Infections - diagnosis; Polyomavirus Infections - epidemiology; Polyomavirus Infections - etiology; Retrospective Studies; Transplant Recipients; Tumor Virus Infections - diagnosis; Tumor Virus Infections - epidemiology; Tumor Virus Infections - etiology; Viremia - diagnosis; Viremia - epidemiology; Viremia - etiology; BKPyV virus serology; BKPyV; BKVPyV serostatus; BKPyV seroprevalence; kidney transplantation; serological technique
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfab279

ABSTRACT
Objectives
BK polyomavirus-associated nephropathy is a troublesome disease caused by BK polyomavirus (BKPyV) infection in immunocompromised renal graft recipients. There are no effective treatments available, making immunosuppression reduction the only management option. Thus, pre-graft predictive BKPyV replication markers are needed for identification of patients at high risk of viraemia.
Methods
We conducted a retrospective study to assess the correlation between pre-transplantation BKPyV serostatus and post-transplantation incidence of BKPyV infection. Sera from 329 recipients and 222 matched donors were tested for anti-BKPyV antibodies against BKPyV serotypes I and IV by using a virus-like particle-based immunoglobulin G enzyme-linked immunosorbent assay, and BKPyV DNA load was monitored for at least 1 year post-transplantation.
Results
Eighty recipients were viruric and 59 recipients were viraemic post-transplantation. In the post-transplantation period, the probability of developing viraemia for serotype I increased from 4.3% for the D−/R+ group to 12.1% for the D+/R+ group, climbing to 37.5% for the D+/R− group (P < 0.05). When calculating recipient mean titres for serotypes I and IV, we observed a clear difference in the proportions of viraemia, decreasing from 50% for mean titres <400 to 13.5% for titres ≥400 (P < 0.001), as well as a higher proportion of presumptive nephropathy (50% versus 23.1%, respectively; P < 0.05). In univariate analysis, this parameter had an odds ratio of 6.41 for the risk of developing post-transplantation BKPyV viraemia (95% confidence interval 3.16–13.07; P < 0.0001).
Conclusions
Determination of both donor and recipient BKPyV seropositivity before transplantation and antibody titre measurements may serve as a predictive tool to manage clinical BKPyV infection by identification of patients at high risk.